22 Jul Struggling biotech Epix to liquidate
Epix, a struggling biotechnology firm working with the British drug maker GlaxoSmithKline to develop an Alzheimer’s disease drug, says it is winding down its operations and selling off assets to pay off creditors.
Read full article>>